Cart
sales@molnova.com
TCS-OX2-29
CAS No. 372523-75-6
TCS-OX2-29( —— )
Catalog No. M19326 CAS No. 372523-75-6
TCS-OX2-29 is a potent and selective OX2 receptor antagonist (IC50: 40 nM). It displays >250-fold selectivity for OX2 over OX1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 35 | In Stock |
|
| 5MG | 58 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 25MG | 170 | In Stock |
|
| 50MG | 250 | In Stock |
|
| 100MG | 447 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTCS-OX2-29
-
NoteResearch use only, not for human use.
-
Brief DescriptionTCS-OX2-29 is a potent and selective OX2 receptor antagonist (IC50: 40 nM). It displays >250-fold selectivity for OX2 over OX1.
-
DescriptionTCS-OX2-29 is a potent and selective OX2 receptor antagonist (IC50: 40 nM). It displays >250-fold selectivity for OX2 over OX1.
-
In VitroTCS-OX2-29 inhibits orexin A induced IP3 accumulation and ERK1/2 phosphorylation in CHO cells transfected with the OX2 receptor.
-
In VivoTCS-OX2-29 (5-10 mg/kg; intraperitoneal injection; adult male NMRI mice) treatment suppresses conditioned place preference (CPP) acquisition and expression in both na?ve and dependent mice significantly. Animal Model:440 adult male NMRI mice (25-30 g)Dosage:5 mg/kg and 10 mg/kg Administration:Intraperitoneal injection (Pharmacokinetic study) Result:Suppressed conditioned place preference (CPP) acquisition and expression in both na?ve and dependent mice significantly.
-
Synonyms——
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetKinesin
-
RecptorOX2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number372523-75-6
-
Formula Weight397.51
-
Molecular FormulaC23H31N3O3
-
Purity>98% (HPLC)
-
SolubilityH2O : < 0.1 mg/mL
-
SMILESCOC1=C(OC)C=C2CN(CCC2=C1)C(=O)[C@@H](NCC1=CC=NC=C1)C(C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hirose M et al. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidicantagonist. Bioorg Med Chem Lett, 2003 Dec 15, 13(24):4497-9.
molnova catalog
related products
-
GSK-923295
The first potent, allosteric inhibitor of CENP-E kinesin motor ATPase activity with Ki of 3.2 nM.
-
Mps1-IN-3
Mps1-IN-3 is an effective and selective inhibitor of MPS1 kinase (IC50: 50 nM).
-
MK-8267
MK-8267 (SCH 2047069) is a potent, orally bioavailable, brain penetrant kinesin spindle protein (KSP) inhibitor with EC50 of 3 nM.
